Completed PHASE1 INTERVENTIONAL 1-arm NCT01598454

Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides

Phase 1 Study on the Use of Racotumomab Anti-idiotype Antibody in Patients With Pediatric Malignancies That Express N-glycolylated Gangliosides and Are Resistant to Conventional Treatment.

Sponsor: Laboratorio Elea Phoenix S.A.

Conditions Ewing's Sarcoma Glioma Neuroblastoma Retinoblastoma Wilm's Tumor

Interventions racotumomab

Updated 6 times since 2017 Last updated: Jul 27, 2015 Started: Feb 28, 2011 Primary completion: Mar 31, 2014 Completion: Jun 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Ewing's Sarcoma and Glioma and is currently completed. Laboratorio Elea Phoenix S.A. leads this study, which shows 6 recorded versions since 2011 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
May 2020 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — May 2020 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Feb 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Laboratorio Elea Phoenix S.A.
Ministerio de Ciencia e Innovación, Spain

Data source: Laboratorio Elea Phoenix S.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Buenos Aires, Argentina